From July 1, 2023 to September 30, 2023, the company has repurchased 80,000 shares, representing 0.67% for CAD 0.6 million. With this, the company has completed the repurchase of 306,700 shares, representing 2.55% for CAD 2.27 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 CAD | +3.16% | -0.12% | -7.81% |
04-22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
04-01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.81% | 70.3M | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.